Renal Anemia

Conflicts and Controversies

Nonfiction, Health & Well Being, Medical, Specialties, Internal Medicine, Nephrology, Hematology
Cover of the book Renal Anemia by , Springer Netherlands
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart
Author: ISBN: 9789401599986
Publisher: Springer Netherlands Publication: June 29, 2013
Imprint: Springer Language: English
Author:
ISBN: 9789401599986
Publisher: Springer Netherlands
Publication: June 29, 2013
Imprint: Springer
Language: English

Is the nephrology community facilitating excess cardiovascular deaths in patients with kidney failure and anemia by treating to a subnormal hematocrit? Why have clinicians and nephrologists permitted health insurance companies and the government to decide when anemia therapy should begin in persons with progressive kidney failure? Is iron the only variable that can be manipulated to maximize response to recombinant erythropoietin? Are we using too much intravenous iron in kidney failure patients, and is oral iron supplementation worthless in sustaining iron stores during long-term erythropoietin treatment? When does left ventricular hypertrophy begin to emerge in patients with progressive renal disease and is there convincing evidence that anemia is a significant cause of LVH in this setting? Is darbepoetin alfa, a new novel, long-acting erythropoietin, really superior to recombinant erythropoietin? This book is a compilation of proceedings from a conference in Brooklyn convened to address these and other controversial and unresolved issues in renal anemia management.

View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart

Is the nephrology community facilitating excess cardiovascular deaths in patients with kidney failure and anemia by treating to a subnormal hematocrit? Why have clinicians and nephrologists permitted health insurance companies and the government to decide when anemia therapy should begin in persons with progressive kidney failure? Is iron the only variable that can be manipulated to maximize response to recombinant erythropoietin? Are we using too much intravenous iron in kidney failure patients, and is oral iron supplementation worthless in sustaining iron stores during long-term erythropoietin treatment? When does left ventricular hypertrophy begin to emerge in patients with progressive renal disease and is there convincing evidence that anemia is a significant cause of LVH in this setting? Is darbepoetin alfa, a new novel, long-acting erythropoietin, really superior to recombinant erythropoietin? This book is a compilation of proceedings from a conference in Brooklyn convened to address these and other controversial and unresolved issues in renal anemia management.

More books from Springer Netherlands

Cover of the book A Treatise of Legal Philosophy and General Jurisprudence by
Cover of the book Global Effects of Environmental Pollution by
Cover of the book SIKU: Knowing Our Ice by
Cover of the book Influence of Tumor Development on the Host by
Cover of the book Quantum Mechanics: Genesis and Achievements by
Cover of the book Dictionary of Ceramic Science and Engineering by
Cover of the book Québec Studies in the Philosophy of Science by
Cover of the book Advanced Nanotechnologies for Detection and Defence against CBRN Agents by
Cover of the book Meinong’s Theory of Knowledge by
Cover of the book Nutritional Epidemiology of Breast Cancer by
Cover of the book Institutional Legal Facts by
Cover of the book Higher Education in the Asia-Pacific by
Cover of the book Privacy and Data Protection Issues of Biometric Applications by
Cover of the book Oral Disease by
Cover of the book The Pacific Arctic Region by
We use our own "cookies" and third party cookies to improve services and to see statistical information. By using this website, you agree to our Privacy Policy